Working together to maximize impact
Drug development works best as a team endeavor. We continuously explore strategic collaborations to advance our pipeline toward commercialization and to further our work in the treatment of both rare diseases and common diseases that have a genetic component.
We are eager to discuss collaborative partnerships utilizing our proprietary RNAi technology.
If you are interested in partnering with us,
contact Christo Shalish, Vice President of Business Development, at BD@edzelkind.com.
